Mirati Therapeutics’ Krazati (adagrasib) Receives EC’s Approval for Advanced Non-Small Cell Lung Cancer (NSCLC)
Shots:
- The EC has granted conditional marketing approval for Krazati followed by the positive opinion from the CHMP in Nov 2023 valid in all 27 EU member states along with Iceland, Norway and Liechtenstein
- The approval is supported by the data from the P-II (KRYSTAL-1) trial evaluating Krazati (600mg, oral, BID) in participants (n=116) with KRASG12C-mutated advanced NSCLC who were on treatment with a Pt-based regimen and an immune checkpoint inhibitor having the 1EPs of confirmed ORR and DOR
- The data from the P-II demonstrated Krazati’s positive benefit-risk profile as required for the conditional approval
Ref: Mirati | Image: Mirati
Related Posts:- Mirati’s Krazati (adagrasib) Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Advanced KRAS-Mutated Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
